LEK-8842, also known as N-methyl-N-(2-propynyl)lysergamide or as TRALA-01, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD. The drug is described as showing serotonin 5-HT2 receptor partial agonistic activity and α-adrenergic receptor agonistic activity based on in-vitro tissue assays that included selective antagonist challenges. Subsequently, it was found to be a potent partial agonist of the serotonin 5-HT2A and 5-HT2B receptors and to show affinity for the serotonin 5-HT2C receptor. LEK-8842 produces effects in animals including serotonin behavioral syndrome, hyperthermia, pressor effects, pupil dilation, and uterine contractions. The chemical synthesis of LEK-8842 has been described. Several analogues of LEK-8842 have been described, for instance LEK-8804 (N-(2-propynyl)lysergamide) among others. LEK-8842 was first described in the scientific literature by 1992. It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals. Subsequently, LEK-8842 was studied and patented by Matthias Liechti and Daniel Trachsel and colleagues in association with Mind Medicine (Definium Therapeutics) in 2023.
See also Substituted lysergamide LEK-8822 (9,10-dihydro-LEK-8842) LEK-8841 (2-bromo-LEK-8842) LEK-8829 (desoxy-LEK-8842) TRALA-12 (likely didehydro-LSD or DDH-LSD)
References
External links TRALA-01 - Isomer Design


